Kadimastem - Stem Cell to Cure Diseases

About Us > Board of Directors

Eli Opper, PhD - Chairman of the Board

Dr. Eli Opper is the former Chief Scientist of the Ministry of Industry, Trade, and Labor in Israel (2002-2002-2011). Prior to his appointment as the Chief Scientist in May 2002, Dr. Opper was a Partner at Giza Venture Capital since 2000. Dr. Opper has held various senior positions at Rafael, Israel's leading defense systems developer including Vice President of Research and Development, Vice President of Advanced Topics, and General Manager of the Electronic Systems Division. Dr. Opper was also the former President of Europe’s Eureka R&D Fund. He has earned his Ph.D. degree in Computer Engineering from the University of Texas, Austin. Dr. Opper also received his B.Sc. and M.Sc. degrees in Electrical Engineering from the Technion.

Yossi Ben-Yossef - Director, Co-Founder

Mr. Ben-Yossef co-founded Kadimastem in 2009, along with Prof. Michel Revel. Prior to Kadimastem, he has been leading investments and taking an active role in successful Biotech/Life Sciences companies in the last 12 years. Among the companies he was involved with are Evogen (TASE: EVGN), Rosetta Genomics (NASDAQ:ROSG), and Biondvax TASE: BNDX. 

Prof. Michel Revel, MD, PhD - Director, Co-Founder

Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.

In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.

Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and serves as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.

Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.

Julien Ruggeri - Director

Mr. Ruggieri serves as Director of Monroe SA, a Luxembourg based investment company, wholly owned by the Batipart group (http://www.batipart.com). Before joining the Batipart Group, Mr. Ruggieri worked at Morgan Stanley Real Estate Funds (MSREF) in New York , after having worked for an American subsidiary of the Arcelor Mittal. He serves as the Chairman of the Board at Maelys SA, Fond Light Ltd. and Vice Chairman at Jardiland SA. He serves as a Member of Board of Directors at Proméo SA, Delta Car Trade SA and Onomo International SAS. He serves as a Representative Member of Supervisory Board at Korian SA. Mr. Ruggieri is a graduate of the European Business School and holds a DESS post-graduate degree in Audit from IAE, Aix-en-Provence and an MBA from the Johnson School at Cornell University.

Professor Joseph Itskovitz-Eldor - MD, DSc.

Professor Itskovitz-Eldor served as the head of the Obstetrics and Gynecology Department at Rambam Medical Center for 22 years, founded the Technion's embryonic stem cell center and is a professor emeritus at the Technion. In addition, Prof. Itskovitz-Eldor initiated the collaboration with James Thomson, of the University of Wisconsin in Madison, which derived the first human embryonic stem cells worldwide, and later in Israel as well.

In the research laboratories headed by Prof. Itskovitz-Eldor, the derivation of embryonic stem cells from a human source and their differentiation into various cell types was researched. Prof. Itskovitz-Eldor has published more than 200 scientific publications, in fields such as embryonic physiology, fertility medicine and pluripotent embryonic stem cells.

Rami Epstein, Adv. - Director

Mr. Epstein is the owner of R. Epstein & Co.; Law Offices, a private practice with emphasis on Commercial and Corporate Law, International Trade Law, Banking, Energy, Hi-tech and Biotech. In addition, Mr. Epstein is the founder of Biondvax Pharmaceuticals Ltd. (TASE:BNDX) and IDgene Pharamaceuticals Ltd.. In addition, Mr. Epstein is a certified mediator, a member of the Legislative Committee for Science and Technology of the Israeli Bar, and Vice President of the Legislative Committee for Environment and Cleantech of the Israeli Bar. Mr. Epstein holds an LL.B from the Hebrew University of Jerusalem, and a LL.M from King's College, University of London.

Avi Bzura - External Director

Mr. Bzura has more than 20 years of experience in the financial industry. Between 2011-2013, Mr. Bzura was CEO of BDRM Finance, a private equity firm. Prior to his role at BDRM, from 1990-2011, Mr. Bzura served in various senior positions in Bank Hapoalim and Bank of Jerusalem, where he was CEO and Chariman of the Board from 2007-2011. Mr. Bzura holds a B.A in Economics from Tel Aviv Univesity, and an MBA from Bar Ilan University.

Avi Meizler - Director

Mr. Meizler is a leading figure in the pharmaceutical industry in South America in general, and in Brazil in particular.   With a group of partners, Meizler recently invested in Nasvax Ltd.   UCB is a partner in his company, Meizler UCB Biopharma.  Meizler is also the joint owner of Advantech, which engages in the development and commercialization of biological drugs.  Mr. Meizler is one of the largest private investors in Brainsway, whose products he distributes in Brazil.  In addition, Mr. Meizler has invested in Therapix Bioscience and the life sciences company Nirolin.

Yigal Fatran - Director

Mr Fatran has over 35 years of financial and industrial experience. Mr. Fatran's resume includes senior positions at Israeli corporations in the biotech hi-tech industry and he serves as a member of the boards of directors of several Israeli companies (both public and private), including Medivie Therapeutics, Electronics Line Ltd. And Jobookit Holdings Ltd..Mr. Fatran holds B.Sc degrees in Computer Science and Economics, both from Bar Ilan University.

David Sultan - Director

Mr Sultan has 20 years of experience in the fields of operational business management, executive advisory and high tech investment operations. His resume includes senior positions at Disneyland Paris, Accenture, Rail Europe and more recently, in charge of new high tech opportunities scouting and analysis as Director of Magical Capital, helping corporates, funds and family offices looking to investing in high tech companies worldwide. He also leads a consulting activity, advising corporate leaders on structuring their business activity, organization and go to market. M. Sultan is a graduate of the EDHEC Business School in Lille, France.

Olivier Samuel - Observer

Mr Samuel serves as CEO since 1997 of Adomasante who recently acquired Darmian, another company specialized in medical services for the elderly populations in France. He also leads a consulting activity in geriatric care management since 2001 for leading operators and brands in medical hardware (Hartmann), nursing homes (Korian), Telco operators (Orange Healthcare) and care insurance (Mederic Malakoff). Mr Samuel is a graduate of the EM Lyon Business School and from Lille’s Health Engineers school.